Rapid-acting antidepressant-like effects of acetyl-l-carnitine mediated by PI3K/AKT/BDNF/VGF signaling pathway in mice

Neuroscience. 2015 Jan 29:285:281-91. doi: 10.1016/j.neuroscience.2014.11.025. Epub 2014 Nov 26.

Abstract

The possible involvement of the PI3K/AKT/BDNF/VGF signaling in rapid-acting antidepressant-like effects of antidepressants has been explored progressively by more studies. However, whether this signaling participates in the antidepressant-like effects of acetyl-l-carnitine (ALC) has not been examined. Herein, we assessed the antidepressant-like effects of ALC using the forced swimming test (FST). Our results demonstrated the dose-effect relationship of acute administration of ALC (5, 25, 50 and 100mg/kg, i.p.) and showed that it dose-dependently decreased the immobility time on FST of mice. In addition, ALC (100 mg/kg, i.p.) also reversed depressive-like behavior and the down-regulation of phosphorylated AKT (pAKT), brain-derived neurotrophic factor (BDNF) and neuropeptide VGF in the hippocampus and prefrontal cortex of mice induced by chronic unpredictable mild stress (CUMS) paradigm. Further, intra-cerebroventricular (i.c.v.) infusions of LY294002 (10 nmol/side), a specific phosphatidylinositol 3-kinase (PI3K) inhibitor, significantly prevented the antidepressant-like effect of ALC (100mg/kg, i.p.). In conclusion, our results demonstrated that ALC exerts rapid-acting antidepressant-like effects that might be mediated by the PI3K/AKT/BDNF/VGF signaling pathway.

Keywords: acetyl-l-carnitine; brain-derived neurotrophic factor; depression; neuropeptide VGF; phosphatidylinositol 3-kinase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcarnitine / pharmacology*
  • Animals
  • Antidepressive Agents / pharmacology*
  • Brain-Derived Neurotrophic Factor / metabolism*
  • Chromones / pharmacology
  • Depressive Disorder / drug therapy
  • Depressive Disorder / metabolism
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Male
  • Mice
  • Morpholines / pharmacology
  • Nerve Growth Factors
  • Neuropeptides / metabolism*
  • Phosphatidylinositol 3-Kinase / metabolism*
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphorylation / drug effects
  • Prefrontal Cortex / drug effects
  • Prefrontal Cortex / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism*
  • Signal Transduction / drug effects
  • Stress, Psychological / drug therapy
  • Stress, Psychological / metabolism
  • Time Factors

Substances

  • Antidepressive Agents
  • Brain-Derived Neurotrophic Factor
  • Chromones
  • Enzyme Inhibitors
  • Morpholines
  • Nerve Growth Factors
  • Neuropeptides
  • Phosphoinositide-3 Kinase Inhibitors
  • Vgf protein, mouse
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Acetylcarnitine
  • Phosphatidylinositol 3-Kinase
  • Proto-Oncogene Proteins c-akt